Commentary

Video

Dr Hernandez-Ilizaliturri on Immunologic Changes in Venetoclax-Treated CLL

Francisco J. Hernandez-Ilizaliturri, MD, discusses findings from a study investigating immunologic changes in patients with CLL treated with venetoclax.

“BCL-2 inhibition with venetoclax could be… used to further enhance the T-cell function of patients, and it can potentially be used to enhance CAR T-cell therapy options, or other T-cell engaging options, for patients with CLL and perhaps other types of lymphomas.”

Francisco J. Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine – Lymphoma, director, Lymphoma Research, head, Lymphoma Translational Research Lab, associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, discusses findings from a multiomic study investigating immunologic changes in patients with chronic lymphocytic leukemia (CLL) who received treatment with venetoclax (Venclexta).

This study found that patients with CLL exhibit T-cell exhaustion, characterized by impaired T-cell function, which likely contributes to their susceptibility to infections and secondary cancers, Hernandez-Ilizaliturri begins. This study showed that treatment with venetoclax, a BCL-2 inhibitor, improved T-cell fitness within 1 month of therapy initiation. This improvement included metabolic reprogramming, where T cells shift to using lipids for energy production—a process associated with enhanced immune responses, he explains.

Additionally, treatment with venetoclax was shown to induce surface changes on T cells, priming them for improved cytotoxic activity against infectious agents and potentially against cancer cells as well, Hernandez-Ilizaliturri notes. A killing assay using standard cell lines showed that T cells that were engineered into CAR T cells after 1 month of venetoclax exposure demonstrated significantly enhanced in vitro lymphoma cell killing efficiency compared with untreated T cells.

These findings indicate that BCL-2 inhibition with venetoclax targets malignant cells and rejuvenates the immune system by enhancing T-cell function, Hernandez-Ilizaliturri emphasizes. This dual mechanism of action positions venetoclax as a potential adjunctive therapy that may improve outcomes with CAR T-cell therapy or other T-cell–engineered immunotherapies in patients with CLL and other lymphomas, he concludes.

Related Videos
Funda Meric-Bernstam, MD
Bhavana Pothuri, MD
Kristen Spencer, DO
Laurence Albigès, MD, PhD
Nirav Shah, MD, MSHP, discusses evaluating zamtocabtagene autoleucel in patients with relapsed/refractory diffuse large B-cell lymphoma.
Bhagirathbhai Dholaria, MBBS
Sairah Ahmed, M.D
Joshua K. Sabari, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center